186 related articles for article (PubMed ID: 38770962)
1. Safety and efficacy of apixaban versus vitamin K antagonists in patients undergoing dialysis: a systematic review and meta-analysis.
Zhang Y; Wang J; Shen N; Jiang J; Xie Y
Ren Fail; 2024 Dec; 46(1):2349114. PubMed ID: 38770962
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists.
Touma L; Filion KB; Atallah R; Eberg M; Eisenberg MJ
Am J Cardiol; 2015 Feb; 115(4):533-41. PubMed ID: 25547937
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
4. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
5. Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Barba M; Yosuico VED; Terrenato I; Sperati F; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD006466. PubMed ID: 29285754
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis.
Kyriakoulis I; Adamou A; Stamatiou I; Chlorogiannis DD; Kardoutsos I; Koukousaki D; Ntaios G
Eur J Intern Med; 2024 Jan; 119():45-52. PubMed ID: 37648582
[TBL] [Abstract][Full Text] [Related]
8. Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study.
Rago A; Papa AA; Cassese A; Arena G; Magliocca MCG; D'Onofrio A; Golino P; Nigro G; Russo V
Am J Cardiovasc Drugs; 2019 Aug; 19(4):421-427. PubMed ID: 30838557
[TBL] [Abstract][Full Text] [Related]
9. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: A systematic review and meta-analysis of randomized controlled trials.
de Lucena LA; Freitas MAA; Souza AKC; Silva CHA; Watanabe JMF; Guedes FL; Almeida JB; de Oliveira RA
J Thromb Thrombolysis; 2024 Mar; 57(3):381-389. PubMed ID: 38281231
[TBL] [Abstract][Full Text] [Related]
10. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
11. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.
Alhousani M; Malik SU; Abu-Hashyeh A; Poznanski NJ; Al-Hasan S; Roth DF; Alsharedi M; Mustafa B
Thromb Res; 2021 Feb; 198():103-114. PubMed ID: 33310644
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.
Reinecke H; Engelbertz C; Bauersachs R; Breithardt G; Echterhoff HH; Gerß J; Haeusler KG; Hewing B; Hoyer J; Juergensmeyer S; Klingenheben T; Knapp G; Christian Rump L; Schmidt-Guertler H; Wanner C; Kirchhof P; Goerlich D
Circulation; 2023 Jan; 147(4):296-309. PubMed ID: 36335915
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment.
Stanton BE; Barasch NS; Tellor KB
Pharmacotherapy; 2017 Apr; 37(4):412-419. PubMed ID: 28117916
[TBL] [Abstract][Full Text] [Related]
14. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis.
Mariani MV; Magnocavallo M; Straito M; Piro A; Severino P; Iannucci G; Chimenti C; Mancone M; Rocca DGD; Forleo GB; Fedele F; Lavalle C
J Thromb Thrombolysis; 2021 Feb; 51(2):419-429. PubMed ID: 33044735
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
16. The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Oh HJ; Ryu KH; Park BJ; Yoon BH
Medicine (Baltimore); 2021 Mar; 100(11):e25216. PubMed ID: 33726018
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
18. Characterizing the Safety Profile of Apixaban Versus Warfarin in Moderate to Severe Chronic Kidney Disease at a Veterans Affairs Hospital.
Herndon K; Guidry TJ; Wassell K; Elliott W
Ann Pharmacother; 2020 Jun; 54(6):554-560. PubMed ID: 31872779
[No Abstract] [Full Text] [Related]
19. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
Jawitz OK; Wang TY; Lopes RD; Chavez A; Boyer B; Kim H; Anstrom KJ; Becker RC; Blackstone E; Ruel M; Thourani VH; Puskas JD; Gerdisch MW; Johnston D; Capps S; Alexander JH; Svensson LG
Am Heart J; 2020 Sep; 227():91-99. PubMed ID: 32693197
[TBL] [Abstract][Full Text] [Related]
20. Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation.
Mavrakanas TA; Garlo K; Charytan DM
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1146-1154. PubMed ID: 32444398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
